Clinuvel Pharmaceuticals (ASX: CUV) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Clinuvel Pharmaceuticals Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Clinuvel Pharmaceuticals (ASX: CUV)
Latest News
⏸️ Investing
Clinuvel shares plunge 35% in February, analysts say "buy"
Share Fallers
Top 5 ASX share price fallers last week
Share Fallers
CLINUVEL share price crashes 10% lower despite coronavirus update
Share Market News
Foolish weekly wrap: ASX shares have worst week since GFC
Share Fallers
These were the worst performing ASX 200 shares in February
Share Fallers
These were the worst performers on the ASX 200 last week
Share Fallers
CLINUVEL share price down 7% after half year profits dive
Share Fallers
These were the worst performing ASX 200 shares last week
Share Market News
CLINUVEL share price races higher following Q2 update
Share Gainers
Why the Metcash share price is outperforming today
Share Market News
Why Clinuvel, Praemium, Resolute, & Zip Co are racing higher
Share Gainers
This beaten down gold stock just got upgraded by a top broker
Frequently Asked Questions
-
Yes, Clinuvel Pharmaceuticals has historically paid one unfranked shareholder dividend a year.
-
Clinuvel Pharmaceuticals generally pays its shareholder dividend in September.
-
Clinuvel Pharmaceuticals does not have a dividend reinvestment plan.
-
Clinuvel Pharmaceuticals Limited listed on the ASX on 13 February 2001.
CUV ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Clinuvel Pharmaceuticals
Clinuvel Pharmaceuticals Ltd (ASX: CUV) is an Australian-based global biopharmaceutical company developing drugs for the treatment of genetic and vascular disorders. Its principal product SCENESSE is a drug for an inherited disorder, erythropoietic protoporphyria, that causes an intolerance to light.
Its pioneering work aims at preventing the symptoms of skin diseases related to exposure to UV radiation and at repigmentation of the skin due to depigmentation disorders. Geographically, the company derives the majority of its revenue from its US and European markets.
